Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Fluoroquinolones Get New Safety Labeling, But Not A REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.


Related Content

Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes
Fluoroquinolones Need REMS With Communication Plan, AdCom Says
Fluoroquinolones: Is Another FDA Safety Step Needed?
Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk


Related Companies